- Home
- CTO vs PCRX Comparison
CTO vs PCRX Comparison
Compare CTO & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- PCRX
- Stock Information
- Founded
- CTO 1902
- PCRX 2006
- Country
- CTO United States
- PCRX United States
- Employees
- CTO N/A
- PCRX N/A
- Industry
- CTO Real Estate Investment Trusts
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CTO Real Estate
- PCRX Health Care
- Exchange
- CTO Nasdaq
- PCRX Nasdaq
- Market Cap
- CTO 580.9M
- PCRX 1.2B
- IPO Year
- CTO N/A
- PCRX 2011
- Fundamental
- Price
- CTO $19.78
- PCRX $26.59
- Analyst Decision
- CTO Strong Buy
- PCRX Buy
- Analyst Count
- CTO 4
- PCRX 10
- Target Price
- CTO $21.50
- PCRX $29.30
- AVG Volume (30 Days)
- CTO 220.6K
- PCRX 892.8K
- Earning Date
- CTO 02-20-2025
- PCRX 02-27-2025
- Dividend Yield
- CTO 7.68%
- PCRX N/A
- EPS Growth
- CTO N/A
- PCRX N/A
- EPS
- CTO 0.61
- PCRX N/A
- Revenue
- CTO $118,662,000.00
- PCRX $694,957,000.00
- Revenue This Year
- CTO N/A
- PCRX $5.14
- Revenue Next Year
- CTO $13.12
- PCRX $2.44
- P/E Ratio
- CTO $32.77
- PCRX N/A
- Revenue Growth
- CTO 16.61
- PCRX 4.40
- 52 Week Low
- CTO $16.16
- PCRX $11.16
- 52 Week High
- CTO $21.15
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- CTO 53.69
- PCRX 77.75
- Support Level
- CTO $19.26
- PCRX $25.06
- Resistance Level
- CTO $19.77
- PCRX $27.10
- Average True Range (ATR)
- CTO 0.35
- PCRX 1.45
- MACD
- CTO 0.04
- PCRX 0.28
- Stochastic Oscillator
- CTO 73.26
- PCRX 86.23
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a Florida-based real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.